MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-03-2026
The Clorox Company Income Statement 2011-2026 | CLX
Annual Income Statement The Clorox Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
15.4 B | 17.9 B | 19.8 B | 17.4 B | 20.9 B | 25.3 B | 21.1 B | 17.4 B | 17.1 B | 17 B | 14.6 B | 11.4 B | 11.3 B | 9.68 B | 9.79 B |
Shares |
124 M | 124 M | 124 M | 123 M | 126 M | 126 M | 128 M | 129 M | 129 M | 129 M | 130 M | 130 M | 131 M | 133 M | 137 M |
Historical Prices |
125 | 144 | 160 | 141 | 167 | 202 | 149 | 137 | 127 | 105 | 110 | 88.7 | 71.1 | 61.2 | 51.8 |
Net Income |
810 M | 280 M | 149 M | 462 M | 710 M | 939 M | 820 M | 823 M | 701 M | 648 M | 580 M | 558 M | 572 M | 541 M | 557 M |
Revenue |
7.1 B | 7.09 B | 7.39 B | 7.11 B | 7.34 B | 6.72 B | 6.21 B | 6.12 B | 5.97 B | 5.76 B | 5.66 B | 5.59 B | 5.62 B | 5.47 B | 5.23 B |
Cost of Revenue |
3.89 B | 4.04 B | 4.48 B | 4.56 B | 4.14 B | 3.66 B | 3.49 B | 3.45 B | 3.3 B | 3.16 B | - | - | - | - | - |
Gross Profit |
3.21 B | 3.05 B | 2.91 B | 2.54 B | 3.2 B | 3.06 B | 2.73 B | 2.68 B | 2.67 B | 2.6 B | 2.46 B | 2.36 B | 2.41 B | 2.3 B | 2.27 B |
Interest Expense |
88 M | 90 M | 90 M | 106 M | 99 M | 99 M | 97 M | 85 M | 88 M | 88 M | 100 M | 103 M | 122 M | 125 M | 123 M |
EBITDA |
219 M | 235 M | 236 M | 224 M | 211 M | 180 M | 1.12 B | 1.14 B | 1.13 B | 1.06 B | 1.01 B | 967 M | 978 M | 1.08 B | 1.09 B |
Operating Expenses |
- | - | - | - | - | - | 1.62 B | 1.55 B | 1.55 B | 1.54 B | 1.46 B | 1.4 B | 1.44 B | 1.4 B | 1.35 B |
General and Administrative Expenses |
1.12 B | 1.17 B | 1.18 B | 954 M | 1 B | 969 M | 856 M | 837 M | 810 M | 806 M | 798 M | 765 M | 807 M | 798 M | 735 M |
All numbers in USD currency
Quarterly Income Statement The Clorox Company
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
122 M | 123 M | 123 M | 123 M | 124 M | 124 M | 124 M | 124 M | 124 M | 124 M | 124 M | 124 M | 124 M | 123 M | 123 M | 123 M | 123 M | 123 M | 123 M | 126 M | 126 M | 126 M | 126 M | 126 M | 125 M | 126 M | 125 M | 126 M | 128 M | 128 M | 128 M | 128 M | 129 M | 129 M | 129 M | 129 M | 128 M | 129 M | 128 M | 129 M | 130 M | 129 M | 130 M | 129 M | 131 M | 129 M | 131 M | 129 M | 130 M | 130 M | 130 M | 130 M | 131 M | 130 M | 131 M | 130 K | 131 M | 132 K | 131 M | 132 M |
Net Income |
157 M | 80 M | - | 186 M | 193 M | 99 M | - | -51 M | 93 M | 22 M | - | -211 M | 99 M | 85 M | 184 M | 150 M | 69 M | 142 M | 211 M | -61 M | 259 M | 415 M | 259 M | 415 M | 185 M | 203 M | 185 M | 203 M | 182 M | 210 M | 182 M | 210 M | 233 M | 192 M | 233 M | 192 M | 149 M | 179 M | 149 M | 179 M | 149 M | 172 M | 149 M | 172 M | 125 M | 90 M | 125 M | 90 M | 115 M | 136 M | 115 M | 136 M | 123 M | 133 M | 123 M | 133 M | 105 M | 130 M | 105 M | 130 M |
Revenue |
1.67 B | 1.43 B | - | 1.67 B | 1.69 B | 1.76 B | - | 1.81 B | 1.99 B | 1.39 B | - | 1.92 B | 1.72 B | 1.74 B | 3.46 B | 1.81 B | 1.69 B | 1.81 B | 3.5 B | 1.78 B | 1.84 B | 1.92 B | 1.84 B | 1.92 B | 1.45 B | 1.51 B | 1.45 B | 1.51 B | 1.47 B | 1.56 B | 3.04 B | 1.52 B | 1.42 B | 1.5 B | 2.92 B | 1.48 B | 1.41 B | 1.44 B | 1.41 B | 1.44 B | 1.34 B | 1.39 B | 1.34 B | 1.39 B | 1.34 B | 1.35 B | 1.34 B | 1.35 B | 1.31 B | 1.34 B | 1.33 B | 1.36 B | 1.32 B | 1.34 B | 1.32 B | 1.34 B | 1.22 B | 1.3 B | 1.22 B | 1.3 B |
Cost of Revenue |
951 M | 833 M | - | 924 M | 948 M | 955 M | - | 1.05 B | 1.12 B | 854 M | - | 1.12 B | 1.1 B | 1.11 B | 2.21 B | 1.16 B | 1.13 B | 1.14 B | 2.27 B | 1.01 B | 1 B | 996 M | 1 B | 996 M | 810 M | 843 M | 810 M | 843 M | 830 M | 885 M | 830 M | 885 M | 807 M | 827 M | 895 M | 827 M | 777 M | 803 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
722 M | 596 M | - | 744 M | 738 M | 807 M | - | 766 M | 866 M | 532 M | - | 800 M | 620 M | 626 M | 1.25 B | 649 M | 558 M | 670 M | 1.23 B | 774 M | 837 M | 920 M | 837 M | 920 M | 639 M | 663 M | 639 M | 663 M | 643 M | 678 M | 643 M | 678 M | 609 M | 673 M | 609 M | 673 M | 629 M | 640 M | 629 M | 640 M | 600 M | 625 M | 600 M | 625 M | 572 M | 578 M | 572 M | 578 M | 555 M | 584 M | 557 M | 585 M | 563 M | 574 M | 563 M | 574 M | 507 M | 546 M | 507 M | 546 M |
Interest Expense |
25 M | 23 M | - | 23 M | 22 M | 21 M | - | 22 M | 26 M | 21 M | - | 24 M | 23 M | 22 M | 45 M | 21 M | 23 M | 25 M | 48 M | 25 M | 24 M | 25 M | 24 M | 25 M | 25 M | 25 M | 25 M | 25 M | 24 M | 24 M | 24 M | 24 M | 20 M | 21 M | 20 M | 21 M | 22 M | 22 M | 22 M | 22 M | 22 M | 23 M | 22 M | 23 M | 26 M | 26 M | 26 M | 26 M | 26 M | 26 M | 26 M | 26 M | 33 M | 33 M | 33 M | 33 M | 30 M | 29 M | 30 M | 29 M |
EBITDA |
55 M | 56 M | - | - | 53 M | 54 M | - | - | - | 61 M | - | 7 M | - | 56 M | 114 M | 8 M | - | 55 M | 110 M | 8 M | - | 51 M | 104 M | 51 M | - | 44 M | 88 M | 44 M | - | 44 M | 88 M | 44 M | - | 40 M | 81 M | 40 M | - | 41 M | 82 M | - | - | 41 M | 82 M | 41 M | - | 43 M | 85 M | 43 M | - | 43 M | 89 M | 44 M | - | 44 M | 90 M | 44 M | - | 46 M | 89 M | 46 M |
General and Administrative Expenses |
262 M | 277 M | - | 267 M | 280 M | 281 M | - | 301 M | 322 M | 276 M | - | 311 M | 282 M | 261 M | 543 M | 233 M | 241 M | 236 M | 477 M | 237 M | 269 M | 238 M | 269 M | 238 M | 210 M | 211 M | 210 M | 211 M | 211 M | 212 M | 211 M | 212 M | 197 M | 204 M | 197 M | 204 M | 197 M | 200 M | 197 M | 200 M | 191 M | 186 M | 191 M | 186 M | 191 M | 180 M | 191 M | 180 M | 196 M | 194 M | 200 M | 198 M | 204 M | 195 M | 204 M | 195 M | 184 M | 190 M | 184 M | 190 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company The Clorox Company (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Household products industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Natura &Co Holding S.A.
NTCO
|
- | - | $ 9.02 B | - |
 |
The Estée Lauder Companies
EL
|
$ 99.17 | -1.02 % | $ 35.7 B |  USA |
 |
Colgate-Palmolive Company
CL
|
$ 95.73 | -1.59 % | $ 77.4 B | USA |
 |
Inter Parfums
IPAR
|
$ 95.49 | -3.72 % | $ 3.06 B | USA |
 |
Coty
COTY
|
$ 2.49 | 0.81 % | $ 2.17 B | USA |
 |
Kimberly-Clark Corporation
KMB
|
$ 104.79 | -4.51 % | $ 34.8 B | USA |
 |
LifeVantage Corporation
LFVN
|
$ 4.77 | 5.53 % | $ 58.4 M | USA |
 |
Nu Skin Enterprises
NUS
|
$ 7.5 | -7.06 % | $ 370 M | USA |
 |
Newell Brands
NWL
|
$ 4.37 | -1.8 % | $ 1.83 B | USA |
 |
Dogness (International) Corporation
DOGZ
|
$ 1.46 | 0.69 % | $ 49.2 M |  China |
 |
Acme United Corporation
ACU
|
$ 44.35 | -2.23 % | $ 164 M | USA |
 |
Helen of Troy Limited
HELE
|
$ 16.91 | -1.4 % | $ 389 M |  Bermuda |
 |
e.l.f. Beauty
ELF
|
$ 81.13 | -0.61 % | $ 4.44 B | USA |
 |
Revlon
REV
|
- | -4.41 % | $ 212 M | USA |
 |
Church & Dwight Co.
CHD
|
$ 103.06 | -0.84 % | $ 25 B | USA |
 |
Mannatech, Incorporated
MTEX
|
$ 6.73 | -1.39 % | $ 12.6 M | USA |
 |
Edgewell Personal Care Company
EPC
|
$ 21.37 | -3.87 % | $ 1.06 B | USA |
 |
Hims & Hers Health
HIMS
|
$ 15.86 | -3.7 % | $ 3.57 B | USA |
 |
Nature's Sunshine Products
NATR
|
$ 27.02 | -2.81 % | $ 515 M | USA |
 |
Unilever PLC
UL
|
$ 69.16 | -3.25 % | $ 132 B |  Britain |
 |
The Procter & Gamble Company
PG
|
$ 159.88 | -2.21 % | $ 376 B | USA |
 |
Spectrum Brands Holdings
SPB
|
$ 78.03 | -0.9 % | $ 2.01 B | USA |
 |
United-Guardian
UG
|
$ 6.5 | 0.15 % | $ 29.9 M | USA |
 |
USANA Health Sciences
USNA
|
$ 19.66 | -1.7 % | $ 378 M | USA |